Background Epithelial ovarian cancer presents at an advanced stage in the majority of women. These women require surgery and chemotherapy for optimal treatment. Conventional treatment is to perform surgery first and then give chemotherapy. However, it is not yet clear whether there are any advantages to using chemotherapy before surgery. Objectives To assess whether there is an advantage to treating women with advanced epithelial ovarian cancer with chemotherapy before cytoreductive surgery (neoadjuvant chemotherapy (NACT)) compared with conventional treatment where chemotherapy follows maximal cytoreductive surgery. Search methods For the original review we searched, the Cochrane Central Register of Controlled Trials (

This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows:To assess the diagnostic accuracy of sentinel lymph node biopsy in the identification of pelvic lymph node involvement in women with apparent early stage endometrial cancer. Sentinel node biopsy for diagnosis of lymph node involvement in endometrial cancer (Protocol)

Analysis 2.12. Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome 12 Toxicity: grade 3 or 4 allergic reaction/drug hypersensitivity......... Analysis 2.13. Comparison 2 EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy compared to chemotherapy alone for the treatment of relapsed epithelial ovarian cancer, Outcome